Drug Development

Articles

Technology can solve enterprise-level problems.

Shop Floor and Top Floor, Unite!

Pradeep Karatgil is from Custom Pharmaceutical Services, Dr Reddy's Laboratories Ltd (India).

Raviraj Pillai is Vice President, Integrated Product Development, at Dr Reddy's Laboratories Ltd (India). ravip@drreddys.com

Orally disintegrating tablets offer numerous advantages compared with traditional tablets and capsules, and can be an effective solution for developing line extensions of currently marketed therapies.

Orally disintegrating tablets: the path to improved patient compliance and enhanced life cycle management

Also, Roche's Avastin trial does not meet endpoint; Innate Pharma names regulatory VP; more...

Company and People Notes: CIGNA and Merck Agree on Drug Pricing Plan; Kathleen Sebelius Confirmed as head of HHS; More

Also: Sanofi-aventis acquires BiPar Sciences; FDA issues Warning Letter to Chinese heparin manufacturer; Halo Pharmaceutical appoints chief scientific officer; more...

Company and People Notes: GSK Acquires Stiefel Laboratories; Roche Announces Changes at Genentech; More...

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

The United States Pharmacopeial (USP) Convention signed a memorandum of understanding (MOU) with the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) last week in Moscow.

USP Forms Collaboration with Russia

Also, Sanofi-aventis acquires Medley and Laboratorios Kendrick; Eli Lilly's Cook to retire from board; more...

Company and People Notes: DSM and Shire Form Pact; Pfizer Names Oncology Unit Exec; More...

Also, Genzyme and Bayer HealthCare form agreement; FDA releases draft guidances; TransMolecular appointed Robert Radie president and CEO

Company and People Notes: BMS and Otsuka Extend Abilify Agreement; Takeda Reorganizes Corporate Structure; More...

The financial crisis is adding further injury to already weakened prospects for the pharmaceutical industry.

A Sobering PharmaChem Outlook

Follow-on biologics or biosimilars offer a niche growth market for the pharmaceutical industry. As the process for establishing a regulatory pathway for biosimilars is debated, companies, including Big Pharma, are positioning themselves to gain this piece of the pharmaceutical pie.

Gauging Opportunities in the Biosimilars Market

The US Senate introduced a bipartisan bill (S. 726) on Mar. 26, 2009, which establishes a regulatory pathway for approval of biosimilars.

Ingredients